Data as of Sep 21, 2026 · Based on 3,332,371 AI responses across 10,526 prompts · See how Parse measures this
SAGA Diagnostics redefines early detection of molecular residual disease (MRD) and offers Pathlight, an ultra-sensitive, blood-based multi-cancer MRD test now commercially available in the U.S. for early-stage breast cancer. Pathlight uses whole-genome sequencing of a patient’s tumor to identify structural variants and creates a personalized, ultra-sensitive multiplex digital PCR assay to detect circulating tumor DNA in blood, targeting variants that remain stable under therapy. Clinical data show high performance, including 96% baseline detection across cancers (94% in ER+ breast cancer) and, in published studies, 100% sensitivity and 100% specificity with a lead time of up to 13.7 months.
Parse Score
No contexts measured yet.
